Amryt Pharmaceuticals Inc. a biopharmaceutical company, engages in the development and commercialization of therapies for patients with debilitating rare diseases. It markets Juxtapid (lomitapide) capsule, a prescription medicine, used along with diet and other lipid-lowering treatments, including low-density lipoprotein apheresis, homozygous familial hypercholesterolemia, total cholesterol, a protein that carries bad cholesterol in the blood (apolipoprotein B), and non-high-density lipoprotein cholesterol. The company also markets Myalept (metreleptin), a leptin replacement therapy, used with a doctor-recommended diet to treat problems caused by not having enough leptin (leptin deficiency) in people with generalized lipodystrophy. In addition, it is developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company was formerly known as Aegerion Pharmaceuticals, Inc. and changed its name to Amryt Pharmaceuticals Inc. in July 2022. Amryt Pharmaceuticals Inc. was incorporated in 2005 and is based in Cambridge, Massachusetts. Amryt Pharmaceuticals Inc. operates as a subsidiary of AMRYT Pharma Holdings Limited